GlassScriptPhysician profile
Neil J Friedman
NPI 1477644334
$12,562.00
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,968 · 2020: $288 · 2021: $4,287 · 2022: $1,821 · 2023: $552 · 2024: $446 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $5,563.57 | 2019-2022 | |
| Sight Sciences, INC. | $2,629.64 | 2019-2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $1,318.34 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $678.55 | 2019-2024 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $446.52 | 2023-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $363.77 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $261.61 | 2019-2021 | |
| Alcon Vision LLC | $261.40 | 2022-2024 | Clareon |
| Solta Medical, A Division of Bausch Health US, LLC | $207.42 | 2019 | |
| Dompe US, INC. | $197.40 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.21 | 2019-2021 | |
| Hoffmann-La Roche Limited | $106.78 | 2019 | |
| Abbvie INC. | $84.86 | 2019-2025 | |
| Allergan, INC. | $81.02 | 2019-2021 | |
| Harrow Eye, LLC | $50.53 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $37.32 | 2019 | |
| Shire North American Group INC | $24.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.95 | 2020 | |
| Rxsight INC | $22.65 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Eyevance Pharmaceuticals LLC | $21.19 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.13 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$115,057.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.